Kiniksa Pharmaceuticals is looking to create a Virtual Recurrent Pericarditis Advisory Board. We’re inviting individuals affected by recurrent pericarditis, both in the US and internationally, to participate in this important…
Due to the Pre-Clinical Data and Initial Clinical Data from Cardiol’s Maverick-Pilot Phase II Study of Pericarditis, it has been granted Orphan Drug Designation for its lead drug candidate for…
Nancy was an active woman whose life was altered drastically after being diagnosed. Learn more about recurrent pericarditis by watching Nancy’s story, feat. Dr. Allan Klein, Director of Cardiovascular Imaging…
The RESONANCE Recurrent Pericarditis Patient Registry Website is now up and running! This Registry will give a voice to people living with recurrent pericarditis. The requirement is that you have…
On March 18, 2021, Kiniksa Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) of ARCALYST (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of…
